Skip to main content

Johnson & Johnson to Host Enterprise Business Review

Johnson & Johnson (NYSE: JNJ) (the ‘Company’) will hold an Enterprise Business Review for the investment community on Tuesday, December 5, 2023. During the event, Company leaders will share a detailed review of the Innovative Medicine and MedTech businesses and their respective pipelines as well as discuss the Company’s long-term strategy to deliver sustained growth and value to shareholders.

Following the ringing of the Opening Bell at the New York Stock Exchange, the Enterprise Business Review will include a live General Session beginning at 10:00 a.m. ET and ending at approximately 3:15 p.m. ET, featuring:

  • Enterprise overview from Chairman and Chief Executive Officer, Joaquin Duato and a financial overview from Executive Vice President, Chief Financial Officer Joe Wolk.
  • Insights into Innovative Medicine’s commercial strategy and transformational innovation fueling both short and long-term growth delivered by Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine R&D.
  • Perspectives on MedTech’s commercial opportunities, recently launched innovations and plans for expansion into higher-growth markets delivered by Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech and Ahmet Tezel, Ph.D., Company Group Chairman, MedTech R&D.
  • Presentations highlighting additional focus areas across the Company’s current and future pipeline; and
  • Q&A sessions with leaders from the Company’s Executive Committee, Research & Development and Commercial teams.

Those planning to attend the event virtually can register and view the agenda and speaker biographies here. A replay and supporting content will be posted by the end of the day on December 5, 2023.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at

Note to Investors Concerning Forward-Looking Statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to realize the anticipated benefits from the separation of the Company’s Consumer Health business; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.